Alector (ALEC) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entrada Therapeutics (TRDA) has outperformed Alector (ALEC) over the past year, losing 4.1% versus a loss of 37.5%. Entrada Therapeutics is the larger company by market cap ($218.4 million vs $214.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | TRDA |
|---|---|---|
| Share price | $1.92 | $5.61 |
| Market cap | $214.38M | $218.43M |
| 1-day change | +6.08% | +3.51% |
| YTD return | +23.08% | -45.43% |
| 1-year return | -37.46% | -4.10% |
| 5-year return | -91.76% | — |
| EPS (TTM) | $-1.09 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $16.45 |
| 52-week low | $1.09 | $5.15 |
| Distance from 52-week high | -43.53% | -65.90% |
| Analyst consensus | hold | none |
| Avg. price target upside | +71.88% | +238.68% |
| Average volume | 2.77M | 359.01K |
| Shares outstanding | 111.66M | 38.94M |
| Employees | 103 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRDA has outperformed ALEC by 33.4 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
ALEC vs TRDA FAQ
Which is bigger, Alector or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $218.43M compared with $214.38M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or TRDA?
TRDA returned -4.10% over the past 12 months, compared with -37.46% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Entrada Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Alector and Biotechnology: Pharmaceutical Preparations for Entrada Therapeutics.